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ABSTRACT 
Objective: To develop and internally validate a prognostic model for perinatal death 
that could guide community-based antenatal care of women with a hypertensive 
disorder of pregnancy (HDP) in low-resourced settings as part of a mobile health 
application. 
Study Design: Using data from 1688 women (110 (6.5%) perinatal deaths) admitted 
to hospital after 32 weeks gestation with a HDP from five low-resourced countries in 
the miniPIERS prospective cohort, a logistic regression model to predict perinatal 
death was developed and internally validated. Model discrimination, calibration, and 
classification accuracy were assessed and compared with use of gestational age 
alone to determine prognosis.  
Main outcome measures: Stillbirth or neonatal death before hospital discharge. 
Results: The final model included maternal age; a count of symptoms (0, 1 or ≥ 2); 
and dipstick proteinuria. The area under the receiver operating characteristic curve 
was 0.75 [95% CI 0.71 - 0.80]. The model correctly identified 42/110 (38.2%) 
additional cases as high-risk (probability >15%) of perinatal death compared with use 
of only gestational age <34 weeks at assessment with increased sensitivity (48.6% 
vs. 23.8%) and similar specificity (86.6% vs. 90.0%).   
Conclusion: Using simple, routinely collected measures during antenatal care, we 
can identify women with a HDP who are at increased risk of perinatal death and who 
would benefit from transfer to facility-based care. This model requires external 
validation and assessment in an implementation study to confirm performance.  
Key Words: pre-eclampsia; prognosis; perinatal death; stillbirth; low-resourced 
setting  
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INTRODUCTION 
Perinatal death, including stillbirth and neonatal death up to 28 days of life, remains a 
significant health burden, globally. By most recent estimates, there were an 
estimated 2.64 million stillbirths in 2009, 76.2% of which were in Sub-Saharan Africa 
or South Asia (1, 2). Global neonatal and child death rates show a similar trend, with 
an estimated 2.00 million early neonatal deaths in 2013 and 80% of all child deaths 
reported in just 26 low- and middle- income countries (3). The hypertensive disorders 
of pregnancy are responsible for an estimated 9-20% of all perinatal deaths (2, 11, 
12, 13, 14). 
Like maternal death, perinatal death is increased in low- and middle- income 
countries compared with high-income countries due to a lack of access to effective 
antenatal and emergency obstetric care, as well as demographic and social risk 
factors which include advanced and very young maternal age, being unmarried, low 
socioeconomic status, illiteracy, and undernutrition. (5-7). As such, the majority of 
these deaths are preventable (4-6), by improving both the access to, and quality of, 
maternal antenatal care (8-10). For women with the hypertensive disorders of 
pregnancy, this improvement in care would include improved diagnosis in the 
community and timely referral to a higher-level facility, should a woman be identified 
to be at risk of a serious complication.  
We have previously developed and validated the miniPIERS (Pre-eclampsia 
Integrated Estimate of RiSk) model that can identify which women with a 
hypertensive disorder of pregnancy are at greatest risk of poor maternal outcome 
(15). This model has been converted into a mobile health (mHealth) application, 
called PIERS on the Move (16), for use by frontline health workers as a decision aid 
for diagnosis and timely triage of women with hypertension identified in the 
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community. In order to broaden the impact of the PIERS on the Move tool and 
facilitate improvements in perinatal outcomes, a complimentary model for community-
level identification of hypertensive pregnant women who are at greatest risk of 
perinatal death is required.  
Using data from the miniPIERS cohort, the objective of this study was to determine if 
the maternal demographics and clinical symptoms and signs measured during 
antenatal surveillance could be used to identify the fetuses at greatest risk of 
perinatal death. 
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MATERIALS AND METHODS 
Study design and population 
The miniPIERS cohort is a prospective, multicentre cohort of women with a 
hypertensive disorder of pregnancy collected from July 2008 – March 2012. A 
detailed description of the cohort has been previously published (15). The study was 
approved by the University of British Columbia clinical research ethics board and 
each participating institutions clinical research ethics board. All participating women 
provided written informed consent for inclusion into the miniPIERS cohort.  
Women were included in miniPIERS if they were admitted to a participating institution 
with any of the hypertensive disorders of pregnancy: chronic hypertension, 
gestational hypertension, pre-eclampsia, or isolated HELLP (Hemolysis Elevated 
Liver enzyme Low Platelet) syndrome. Women were excluded if: (i) they had suffered 
a primary maternal outcome for the main study prior to admission to hospital, or (ii) 
they had been admitted to hospital with either a CD4 count <250 or an AIDS-defining 
illness, as these were felt to be significant confounders of the disease-maternal 
outcome relationship. These inclusion and exclusion criteria have been previously 
described (15).  
For this study, the cohort was further restricted to include only singleton pregnancies 
and cases with admission after 32 weeks gestation, to optimize the clinical relevance 
of the model. First, perinatal risk in the very early preterm period before 32 weeks 
gestation would be driven almost entirely by gestational age. Second, in under-
resourced settings, neonatal survival is unlikely when delivery occurs prior to 32 
weeks, but thereafter, survival is likely in any setting with basic newborn care (17). 
Having a model that identifies those women likely to benefit from facility-based care 
for their high-risk neonates after 32 weeks gestation is therefore needed.  
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Candidate predictor variables 
For this study, candidate predictor variables were defined prior to analysis as: (i) 
those demonstrated to increase risk of stillbirth or neonatal death in previous studies 
(19, 20) as well as (ii) those related to the severity of the maternal condition in the 
miniPIERS model (15). Specifically, we assessed gestational age on admission 
(weeks), parity (primaparous or multiparous), maternal age (years), smoking status 
(non-smoker/smoker), blood pressure (mmHg), dipstick proteinuria, and the maternal 
symptoms of headache, visual disturbances, chest pain, dyspnoea, right upper 
quadrant pain or epigastric pain, nausea/vomiting, and vaginal bleeding with 
abdominal pain.  
The value of the candidate predictor used in the model development process was the 
worst measured within the first 24hrs of admission. There was no missing data for 
candidate predictors within this timeframe in the miniPIERS cohort. As this was a 
secondary analysis of the existing cohort, during ascertainment of the predictor 
variables data collectors were unaware of the outcome status of the baby.  
Perinatal outcome 
A composite of stillbirth or neonatal death was used to define the primary outcome. 
The study cohort was restricted to those women admitted after 32 weeks gestation, 
so only cases of stillbirth occurring after admission at this time point are considered. 
Neonatal death was limited to that occurring during hospital admission, as follow-up 
post-discharge for women or their babies was not possible.  
Sample size 
The sample size required for model development was determined based on the 
minimum standard of 10 events per effective variable considered, according to the 
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formula N=(nx10)/I where N is the sample size, n is the number of candidate 
predictor variables and I is the estimated event rate in the population (21). As this 
was a secondary analysis of an existing cohort of known size, this formula was used 
to determine the number of candidate predictor variables that could reasonably be 
tested in a multivariable model. Based on a perinatal death rate of 6.5% in the 
miniPIERS cohort and the cohort size of 1688 women, we determined that a 
maximum of 10 candidate predictor variables should be considered. 
Statistical analysis 
Descriptive analysis of the cohort 
Women with and without perinatal death were compared using the Mann-Whitney U 
test for continuous variables and the chi-squared or Fischer’s exact test for 
categorical variables.  
Selection of candidate predictor variables 
Associations with perinatal death were estimated using logistic regression to 
determine univariate and gestational age-adjusted odds ratios for all candidate 
predictor variables. Also, associations between candidate predictor variables were 
estimated by using either the Pearson product moment correlation coefficient or two-
by-two tables and the chi-squared statistic, where appropriate; this was done in order 
to reduce possible correlation between predictor variables included in the model. 
Final predictor variables to be included in the multivariable model were selected 
based on the strength of the gestational age-adjusted association with perinatal 
death, as well as the lack of evidence of correlation with other predictors. A final 
selection rule based on a minimum change in area under the receiver operating 
characteristic curve (AUC ROC) of 0.2 after inclusion of the candidate predictor 
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variable being considered was implemented to ensure that the final model was as 
parsimonious as possible, given the environment in which it is meant to be used.  
Final model development and evaluation 
Multivariable logistic regression was used to estimate the strength of association 
between the final predictors included in the model with perinatal death, the primary 
outcome. This final model was evaluated based on discrimination ability using the 
area under the receiver-operating-characteristic curve (AUC ROC). An AUC ROC 
≥0.70 is considered as evidence of good discrimination (22). 
Calibration of the final multivariable model was assessed based on the Hosmer-
Lemeshow goodness-of-fit test and, visually, by plotting predicted probability of 
perinatal death against the observed rate of the outcome in each decile. Stratification 
capacity of the model was tabulated in five groups of predicted probability as the 
number of events in each group out of the total cases in that group. Groups were 
defined so that the lowest and highest groups included only those women with 
significantly lower or higher predicted probabilities than the population prevalence of 
perinatal death (6.5%). Predictive performance, defining high-risk cases based on the 
threshold of predictive probability used to define each of the five risk groups, was 
estimated using the sensitivity, specificity, positive predictive value and negative 
predictive value. Finally, a likelihood ratio was estimated for each risk group 
individually (23). 
Model validation 
Internal validity of the final multivariable model was assessed using Efron’s enhanced 
bootstrap method (24). Also, evaluation of the final model for classification accuracy 
was based on a comparison with both the published miniPIERS model and 
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gestational age alone. To accomplish this, a classification table was used in which 
women were classified as high-risk based on a miniPIERS maternal model predicted 
probability ≥25% or a gestational age at admission <34 weeks; these results were 
compared with the perinatal model using a risk-threshold of >15% predicted 
probability of perinatal death. Gestational age alone was chosen as a comparator to 
reflect the standard of practice in the study settings; it is the most commonly used 
indicator for risk of stillbirth and neonatal death in this population.  
Sensitivity analyses were performed to assess the performance of the model based 
on its discrimination ability when the outcome was restricted to either stillbirth or 
neonatal death before discharge. Further sensitivity analyses assessed the 
performance of the model when the cohort was restricted to those women admitted 
after 34 weeks gestation or after 36 weeks gestation. 
All statistical analyses were performed using STATA version 13.1 (STATA Corp, 
Texas, US).   
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RESULTS 
Of the 2081 women in the miniPIERS cohort, 1688 (81.1%) were included in this 
study after exclusion of 78 cases with multiple gestation and 323 cases admitted prior 
to 32 weeks gestation. Among these 1688 women, there were 110 (6.5%) perinatal 
deaths, of which 79 were stillbirths and 31 were neonatal deaths prior to hospital 
discharge. Only 6.9% of those neonates who survived remained in hospital for follow-
up to 7 days postpartum. 
Women who had a perinatal death, compared with those who did not, showed more 
severe maternal disease indicators, such as earlier gestational age at admission, 
higher median blood pressure and dipstick proteinuria values, greater occurrence of 
symptoms and higher incidence of adverse maternal outcomes (Table 1). However, 
there was no difference between the groups in the rate of delivery due to maternal 
indication. Women who had a perinatal loss were less likely to be delivered by 
cesarean, an association that was more pronounced when the outcome was 
restricted to stillbirth alone (OR 0.32 [95% CI 0.22-0.48] vs. OR 0.21 [95% CI 0.13-
0.36], respectively). 
The univariate risk factors for perinatal death in this cohort were gestational age at 
admission, blood pressure (both systolic and diastolic), dipstick proteinuria and all 
maternal symptoms. In order to make interpretation of the impact of systolic blood 
pressure more clinically meaningful, the univariate and multivariate odds ratio 
reported for this variable reflect a 10 mmHg change in blood pressure value (Table 
2). 
Selection of candidate predictors for model development 
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Systolic and diastolic blood pressures were highly correlated. Based on the strong 
association found in previous studies between systolic blood pressure and stroke risk 
(25), and the fact that it can be measured without a manometer, it was decided to 
retain systolic blood pressure for consideration in the final model.  
All symptom variables were associated with each other (p<0.001 for the chi-squared 
test). To avoid potential errors in estimation due to multicollinearity, a count of 
symptoms present categorized as zero, one, or greater than or equal to two was 
retained for the final model.  
Maternal age was retained for the final model despite its lack of significance in the 
univariable analysis, as maternal age is a well-established risk factor for perinatal 
death within this population (14). 
When  the requirement that AUC ROC increase by ≥0.02 in order for a variable to be 
included in the final model, symptoms, dipstick and maternal age were selected as 
the most significant contributors to model performance. Addition of blood pressure to 
the model did not have any effect on AUC ROC compared to a model without blood 
pressure (AUC ROC 0.753 vs. 0.753) and addition of gestational age at admission 
had only minimal effect on the AUC ROC (AUC ROC 0.753 vs. 0.761).   
Final multivariate model 
The equation for the final perinatal death model was: logit (logarithm of the odds)(pi)= 
-4.75 + 0.024(maternal age) + 0.389(indicator for presence of one symptom) + 
1.338(indicator for presence of two or more symptoms) + 1.119(indicator for dipstick 
proteinuria of 2+ or 3+) + 1.457(indicator for dipstick proteinuria of 4+).  
Performance of the model 
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Discrimination ability of the model was good with an AUC ROC of 0.75 [95% CI 0.71 - 
0.80] (Figure 1). Among these women who were admitted at 32 weeks or beyond, 
gestational age alone as a predictor of perinatal death was associated with an AUC 
ROC of 0.60 [95% CI 0.54 - 0.66]. When the miniPIERS maternal model was used to 
predict perinatal death in this study, the AUC ROC was 0.70 [95% CI 0.65 - 0.75].  
This model was well-calibrated with a Hosmer-Lemeshow goodness of fit test statistic 
of 2.14 (p=0.98). The calibration of the model is further demonstrated by the model 
calibration curve, where the 95% confidence interval around the observed rate of 
outcome in each decile group of predicted probability crosses the perfect fit line 
(Figure 2).  
Stratification of the cohort based on the model is moderate, with the majority of 
women (54.9%) estimated to have a probability of perinatal death less than 5% and 
25% of whom have a predicted probability <2%, which is significantly less than the 
overall prevalence within the cohort. Sixteen percent of the women were assigned a 
predicted probability in the highest risk group (Table 3).  
Table 3 shows the sensitivity, specificity, positive and negative predictive values 
differed based on the threshold used to define a positive test (i.e. women at high-risk 
of a perinatal loss). As the threshold used to define high-risk increases, the sensitivity 
decreases but the likelihood ratio increases. In no risk group does the likelihood ratio 
result in values that would indicate that the test could be used to clearly rule-in or 
rule-out the risk of perinatal death. Using gestational age at delivery less than 34 
weeks to define a high-risk subgroup in this cohort was associated with a sensitivity 
of 23.6%, specificity 90.0%, positive predictive value 14.1% and negative predictive 
value 94.4%. 
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Model validation  
After 500 iterations of bootstrapping, model optimism was estimated as 0.01 
indicating minimal overfitting of the model to the data.  
The final perinatal death model correctly identifies significantly more high-risk women 
compared with either gestational age only (42/110, 38.2% additional women, Table 
4a) or the miniPIERS maternal model (35/110, 31.8% additional women, Table 4b). 
This improvement in classification of true positive cases occurred with a small 
increase in the false-positive rate compared with using gestational age alone 
(213/1578, 13.5% vs. 159/1578, 10.1%, respectively) or the miniPIERS maternal 
model (213/1578, 13.5% vs. 101/1578, 6.4%, respectively).  
The sensitivity analysis to assess performance of the model using stillbirth or 
neonatal death before discharge as the primary outcome, or when restricting the 
cohort to greater than 34 weeks or 36 weeks gestation on admission, demonstrated 
that the model’s discrimination ability was well maintained (Table 5).  
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DISCUSSION 
In this study we have developed and internally validated a novel perinatal risk model 
using simple measures available at antenatal assessment. Previous work to predict 
risk of stillbirth or perinatal death has been restricted to high-resource neonatal 
intensive care settings and very preterm infants (26). Similarly, the existing neonatal 
risk scores, such as the CRIB II score, are designed for use in an advanced neonatal 
intensive care settings and rely on data available at birth. This is not comparable in 
scope or proposed environment to our model, which is designed for use in a low-
resourced community setting prior to delivery to identify those fetuses at risk of 
perinatal death and for whom facility-based care should be a priority.  
The model developed in this study improves our ability to correctly identify women 
whose fetuses are at risk of perinatal death beyond that of gestational age alone or 
the miniPIERS maternal model.  Addition of this perinatal model to the miniPIERS 
maternal risk model as part of the PIERS on the Move mHealth application (16) 
would result in an improvement in community-level triage by identifying approximately 
38% more women at increased risk of perinatal loss as a result of a hypertensive 
disorder of pregnancy. This would bring us closer to the ultimate goal of supporting 
scale-up of community level antenatal care, including effective diagnosis and triage of 
the hypertensive disorders of pregnancy, and ultimately, to reduce maternal and 
perinatal deaths.  
The data for this study were taken from the miniPIERS cohort, designed for maternal 
outcome prediction, and this may have limited the final predictive performance of a 
perinatal risk model. The miniPIERS cohort may be missing important potential risk 
factors for stillbirth and neonatal death but no such omissions were identified based 
on published literature. This was a secondary analysis of an existing cohort, so we 
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were unable to gather additional data in order to test a greater number of candidate 
predictors. A second limitation of the study was use of a composite perinatal mortality 
outcome.  It could be argued that stillbirth and neonatal death will have distinct risk 
factors and should be modeled separately, given that they often have distinct causes. 
For example, late neonatal deaths are often related to postnatal infection and 
undernutrition. It is also important to mention that the study cohort did not include 
complete follow-up to 28 days postpartum for most neonates and had only limited 
follow-up to 7 days postpartum (7% completeness). This lack of follow-up means late 
neonatal deaths were not recorded and the model is skewed towards prediction of 
events proximate to birth. Combining stillbirth and immediate neonatal death does 
reflect known limitations in our ability to differentiate these two events during data 
collection, as well as the routine practice of combining these events in pre-
established epidemiologic surveillance (27). A final limitation of this study is the use 
of gestational <34 weeks as the “gold-standard” comparator for predictive 
performance of the model. This variable was chosen as it reflects common practice in 
the study settings of basing assessment of risk of perinatal loss on gestational age 
alone. There is no other established gold-standard prognostic test for this purpose.  
Among the strengths of our study is that it is based on a large cohort of well-
characterized women from five LMICs, making results applicable across multiple 
under-resourced settings. Second, by focusing on women admitted at or after 32 
weeks gestation, we have assessed risk factors for perinatal death beyond 
gestational age alone and removed some of the effect of prematurity on the 
occurrence of our primary outcome. In addition, by focusing on only those predictor 
variables that add significantly to the performance of the final model we have been 
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able to develop a simple and useful model given the data available on assessment in 
a community setting, making its implementation by community health workers easier. 
Any intervention applied in an under-resourced setting should demonstrate added 
value above what already exists, while considering resource and health system 
implications. In this case we would increase rates of urgent referral from the 
community by approximately 9.0%, above what would have been indicated by the 
maternal model alone, in order to identify an additional 30% of high-risk women. Put 
differently, for every 1000 hypertensive pregnant women identified, an additional 90 
would be urgently referred to facility to avoid not referring 21 women who would 
suffer certain perinatal death in the community. We believe this to be a reasonable 
trade-off, even though all of those perinatal deaths would not necessarily be 
avoidable, due to factors such as very preterm gestational age.   
In conclusion, this model shows great promise as a tool to identify those hypertensive 
pregnant women at greatest risk of perinatal death. The model requires further 
validation in a new cohort, but once this has been accomplished, the model could be 
incorporated into the PIERS on the Move tool and evaluated in an implementation 
study that would have the potential to reduce maternal and perinatal mortality 
simultaneously. 
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Table 1: Demographics of women in the total cohort comparing women with and 
without perinatal death (N=1688). Results for continuous variables presented as 
mean (± sd) when data normally distributed or median [interquartile range] for 
skewed data.  
 
Characteristic  Women with 
adverse 
neonatal 
outcomes 
(n=  110 
women)  
Women without 
adverse 
neonatal 
outcomes  
(n=  1578 
women)  
P*  
 
Demographics (within 
48h of eligibility)  
      
Maternal age at EDD (yr)  28 [25, 32] 28 [24, 32] 0.336 
Age >40 years 7 (6.3%) 73 (4.6%) 0.407 
Gestational age at 
admission (wk)  
36.6 [34.1, 38.6] 37.6 [35.9, 39.1] <0.001 
Parity ≥ 1 61 (55.5%) 824 (52.2%) 0.554 
Smoking in this pregnancy  1 (0.9%) 47 (3.0%) 0.366 
Hypertensive disorder 
description 
   
Pre-eclampsia  91 (82.7%) 911 (57.7%) <0.001 
miniPIERS maternal 
predicted probability (%) 
12.2 [7.6, 22.3] 7.2 [5.2, 11.7] <0.001 
Clinical measures (within 
24h of eligibility)  
   
   Systolic BP  160 [150, 180] 150 [140, 170] <0.001 
  Diastolic BP  110 [100, 120] 100 [90, 110] <0.001 
Worst dipstick proteinuria  2+ [2+, 3+] 1+ [negative, 3+]  <0.001 
Maternal symptoms    
Headache 77 (70.0%) 640 (40.6%) <0.001 
Visual disturbances 52 (47.3%) 335 (21.2%) <0.001 
Chest pain 7 (6.4%) 35 (2.2%) 0.017 
Dyspnoea 11 (10.0%) 60 (3.8%) 0.005 
Epigastric / right upper 
quadrant pain 
47 (42.7%) 222 (14.1%) <0.001 
Abdominal pain with 
vaginal bleeding 
20 (18.2%) 113 (7.2%) <0.001 
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Nausea / vomiting 43 (39.1%) 215 (13.6%) <0.001 
Interventions at any time    
Corticosteroid 
administration  
41 (37.3%) 348 (22.1%) 0.001 
Antihypertensive 
medications administered  
105 (95.5%) 1457 (92.3%) 0.345 
MgSO4 administered 66 (60.0%) 638 (40.4%) <0.001 
Maternal indication for 
delivery 
91 (82.7%) 1224 (77.6%) 0.204 
cesarean delivery 42 (38.2%) 1034 (65.5%) <0.001 
Pregnancy outcomes     
Admission-to-delivery 
interval (all cases) (d)  
1 [1, 3] 1 [1, 4] 0.102 
Delivery-to-discharge or 
death interval (d) Ŧ 
2 [2, 4] 3 [2, 4] 0.098 
Gestational age on delivery 
(wk) 
36.8 [34.3, 39.3] 38.0 [36.6, 39.3] <0.001 
Birth weight (g)  1801.3 (± 771.7) 2758.7 (± 653.7) <0.001 
Birth weight <3rd percentile 
(N babies) 
51 (46.4%) 254 (16.1%) <0.001 
Maternal adverse outcome 37 (33.6%) 234 (14.8%) <0.001 
BP = blood pressure; EDD = estimated date of delivery; HDP = hypertensive disorder 
of pregnancy; MgSO4 = magnesium sulphate 
*P values calculated using chi-squared test for categorical variables or Mann-Whitney 
U for continuous variables, as appropriate.  
Ŧ excluding stillbirth cases.  
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Table 2: Univariate and adjusted analysis of predictors for perinatal death.  
 
Candidate predictor Univariate Adjusted for gestational 
age at admission 
 OR 
[95% CI] 
OR 
[95% CI] 
Age at EDD (years) 1.01 [0.98 - 1.05] 1.01 [0.98 - 1.04] 
Gestational age at 
admission (weeks) 0.85 [0.79 - 0.92] n/a 
Parity ≥1 1.14 [0.77 - 1.68] 1.09 [0.74 - 1.62] 
Smoking (y/n) 0.30 [0.04 - 2.19] 0.27 [0.04 - 1.95] 
Systolic BP  
(10 mmHg) 1.16 [1.08 - 1.24] 1.13 [1.05 - 1.22] 
Diastolic BP  
(10 mmHg) 1.34 [1.21 - 1.49] 1.33 [1.19 - 1.48] 
Proteinuria 
Negative/trace/ 1+ 
2+/ 3+ 
4+ 
 
Reference 
4.48 [2.71 - 7.40] 
6.71 [3.62 - 12.5] 
 
Reference 
4.13 [2.49 - 6.85] 
6.24 [3.35 - 11.61] 
Pre-eclampsia (y/n) 3.51 [2.12 - 5.81] 3.12 [1.87 - 5.20] 
Symptoms (y/n) 
Headache 
Visual disturbances 
Chest pain 
Dyspnoea 
RUQ pain 
Nausea/vomiting 
Abdominal pain 
 
Number of symptoms 
0 
1 
≥2 
 
3.42 [2.25 - 5.20] 
3.33 [2.24 - 4.93] 
3.00 [1.30 - 6.91] 
2.81 [1.43 - 5.52] 
4.56 [3.04 - 6.82] 
4.07 [2.70 - 6.13] 
2.88 [1.71 - 4.85] 
 
 
reference 
1.99 [1.12 - 3.55] 
6.44 [3.98 - 10.42] 
 
3.36 [2.20 - 5.12] 
3.29 [2.21 - 4.89] 
2.76 [1.18 - 6.44] 
2.95 [1.49 - 5.84] 
4.23 [2.82 - 6.36] 
4.06 [2.69 - 6.13] 
3.03 [1.79 - 5.13] 
 
 
reference 
1.97 [1.10 - 3.52] 
6.28 [3.87 - 10.19] 
BP= blood pressure; EDD= estimated date of delivery; OR= odds ratio; RUQ= right 
upper quadrant 
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Table 3: Risk stratification table to assess the performance of the model for predicting 
perinatal outcome at varying cut-off values to define a positive test. 
 
Predicted 
probability 
# event/ # in 
range (%) 
Sens  Spec  PPV  NPV  LR [95% CI] 
0.0% - 1.9% 7/415 
(1.7%) 
n/a n/a n/a n/a 0.24[0.11-
0.53] 
2.0% - 5.0% 15/511 
(2.9%) 
93.6% 29.2% 8.4% 98.5% 0.43[0.26-
0.69] 
5.1% - 8.0% 24/372 (6.5%) 
79.8% 57.3% 11.5% 97.6% 0.99[0.68-
1.43] 
8.1% - 15% 10/123 (8.1%) 
57.8% 79.4% 16.2% 96.5% 1.26[0.68-
2.35] 
>15.0%  54/267 
(20.2%) 
48.6% 86.6% 20.0% 96.1% 3.64[2.90-
4.57] 
LR= positive likelihood ratio (calculated using the method of Deeks et al.); 
NPV=negative predictive value; PPV=positive predictive value; Sens=sensitivity; 
Spec=specificity 
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Table 4: Classification table to compare classification accuracy of the final model 
(using a predicted probability of >15.0% to define high-risk) vs. (a) gestational age 
alone (using a gestational age of 32-34 weeks at delivery to define high-risk) or (b) 
the published miniPIERS model (using predicted probability ≥25% to define high-risk) 
 
(a) GA alone Final multivariate model Total 
Women with 
events 
Low-risk High-risk 
 
Low-risk 42 42 84 
High-risk 14 12 26 
Total 56 54 110 
Women without events 
  
Low-risk  1230 189 1419 
High-risk 135 24 159 
Total 1365 213 1578 
 
(b) miniPIERS 
maternal model 
Final multivariate model total 
Women with 
events 
Low-risk High-risk 
 
Low-risk 54 35 89 
High-risk 2 19 21 
Total 73 47 110 
Women without events 
  
Low-risk  1359 118 1477 
High-risk 45 56 101 
Total 1404 174 1578 
GA= gestational age 
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Table 5: Results of sensitivity analyses performed using various outcome definitions 
 
Cohort description n/N  AUC ROC [95% CI] 
Including only stillbirth as 
adverse neonatal 
outcome 
79/1686 0.78 [0.73, 0.82] 
Including only neonatal 
death before discharge as 
adverse neonatal 
outcome 
32/1686 0.68 [0.57, 0.78] 
Including only cases with 
gestational age >34 
weeks at onset of disease 
84/1502 0.74 [0.68, 0.80] 
Including only cases with 
gestational age >36 
weeks at onset of disease 
62/1226 0.73 [0.66, 0.80] 
*AUC ROC = area under the receiver operating characteristic curve 
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Figure 1: Receiver operating characteristic curve for the final miniPIERS perinatal 
death model including maternal age (years), dipstick proteinuria (negative/ trace/ 1+ 
vs. 2+/ 3+ or 4+) and a count of symptoms present (0 vs. 1 or ≥2). 
 
 
Figure 2: Calibration plot of the miniPIERS neonatal outcome model red line 
represents line of perfect fit between observed and predicted outcomes. 
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HIGHLIGHTS: 
• Symptoms, dipstick proteinuria and maternal age identify fetuses at risk of perinatal 
death. 
• The area under the receiver operating characteristic curve of the model was 0.75 [95% 
CI 0.71 - 0.80] 
• This perinatal risk model improves detection of perinatal risk beyond gestational age 
alone. 
 
